Dr. Andrew Lewis, Quotient Sciences' Global VP, Integrated Pharmaceutical Sciences will be presenting on May 12th at the 49th editiuon of the Interpharm Conference being held in the UK. Dr Lewis' presentation is entitled 'Oral Peptide Delivery - Are we there yet?'.
As the therapeutic landscape has evolved from small-molecule drugs to a new generation of therapeutics, including peptides, drug delivery technologies have also evolved to meet their unique delivery needs. Are we there yet with oral peptide delivery?
About the 49th Interpharm Conference
As the pharmaceutical world is ever changing and continues to increase in both complexity and speed, how does the pharmaceutical sciences ecosystem work together to accelerate the delivery of life-changing medicines for patients. Science, scientists and the future will meet at the Interpharm Conference.
About Dr Andrew Lewis
Andrew is currently Global Vice President Integrated Pharmaceutical Science at Quotient Sciences and is responsible for our pharmaceutical development services across both the UK and USA. After obtaining his pharmacy degree and PhD from the University of Nottingham he has worked in the pharmaceutical industry for over 20 years for organisations of all sizes – from start-up biotechs (RegenTec, Critical Pharmaceuticals) to larger pharmaceutical companies (Ipsen, Pfizer). He has a passion for the application of advanced drug del ivery technologies to address unmet clinical needs, particularly in the areas of protein and peptide drug delivery, solubility enhancement and controlled release. He is a member of the Academy of Pharmaceutical Scientists of Great Britain and was twice elected to the board of directors of the Controlled Release Society (CRS) where he served for a number of years as Director-at-Large and Secretary
If you have any questions about Oral Peptides or any other drug development queries you can in get in touch with our expert Dr. Andrew Lewis, here.